Women who take certain antidepressant drugs while pregnant may double their child’s risk of being born with a certain variety of heart defect, according to a study conducted by researchers from Aarhaus University in Denmark and published in the medical journal BMJ.
GlaxoSmithKline has paid out close to $1 billion to resolve lawsuits involving Paxil since the drug came on the market in 1992, according to a December 14, 2009 Bloomberg report. But the billion dollars does not cover the more than 600 Paxil birth defect cases currently pending in multi-litigation in Pennsylvania.
Taking Prozac, Paxil, or other antidepressants from the class of drugs called selective serotonin reuptake inhibitors (SSRIs) can cause delays in lactation in new mothers and difficulty in breast-feeding newborns, a new study says. Researchers from the University of Cincinnati found SSRIs can result in delayed secretory activation after giving birth. SSRIs regulate the hormone serotonin in the body to stave off depression, but the hormone also is crucial to the breasts’ ability to deliver milk when it is needed, the study’s authors said.
Doctors still routinely reassure patients that the side-effects of antidepressants are largely mild and short term – these include drowsiness, dizziness and weight gain that become obvious in the first few weeks and can normally be reversed by trying another type of pill. Yet there is growing evidence that long-term use is linked to more serious health problems including bleeding in the gut, low sodium levels in the elderly (which can lead to falls) and increased risk of stroke. Recently it’s been claimed that some antidepressants may increase the risk of birth defects.
Michelle David filed a lawsuit against GlaxoSmithKline, alleging the company’s antidepressant, Paxil was responsible for her son’s birth defects. David said she had taken Paxil while pregnant and was not aware of the potential side effects. The jury also found that Paxil was a factual cause of the little boy’s heart problems. David was awarded $2.5 million.